Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

74.54 -0.60 (-0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
News headline image
DexCom (DXCM) Q2 2026 Earnings Call Transcript ↗
Revenue hit $1.31 billion with strong international growth and margin expansion. 
Via The Motley Fool
Topics Earnings
News headline image
DexCom Q2 Earnings Call Highlights ↗
DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and... 
Via MarketBeat
Topics Earnings
Which S&P500 stocks are moving after the closing bell on Thursday? ↗
Via Chartmill
Dexcom (NASDAQ:DXCM) Beats Q2 Earnings Estimates, Raises Profitability Guidance ↗
Via Chartmill
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup ↗
Via Chartmill
DexCom (NASDAQ:DXCM): An Affordable Growth Pick With Strong Momentum and Financial Health ↗
Via Chartmill
DexCom Inc (NASDAQ:DXCM) Passes Rigorous Quality Screen with Strong Profitability and Growth Metrics ↗
Via Chartmill
News headline image
DexCom’s (NASDAQ:DXCM) Q2 CY2026 Sales Beat Estimates
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q2 CY2026, with sales up 13.1% year on year to $1.31 billion. The compa... 
Via StockStory
Topics Earnings
News headline image
Dexcom Reports Second Quarter 2026 Financial Results
From DexCom, Inc.
Via Business Wire
News headline image
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗
They may profit from the rapidly growing GLP-1 market in very different ways. 
Via The Motley Fool
News headline image
DexCom Earnings: What To Look For From DXCM
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what to look for. DexCom beat analysts’ revenue ex... 
Via StockStory
Topics Artificial Intelligence
News headline image
Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
From DexCom, Inc.
Via Business Wire
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
1 Mid-Cap Stock to Target This Week and 2 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
News headline image
Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including DexCom (NASDAQ:DXCM) a... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Nasdaq 100 Stocks with Promising Prospects
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a ... 
Via StockStory
News headline image
Dexcom Further Advances Vision of Glucose Biosensing for All
From DexCom, Inc.
Via Business Wire
News headline image
Should You Buy Abbott Labs Stock Hand Over Fist Before July 16? ↗
July earnings matter, but long-term growth matters more. 
Via The Motley Fool
News headline image
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out. 
Via MarketBeat
Topics ETFs
News headline image
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound ↗
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound. 
Via MarketBeat
News headline image
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 Reasons Investors Love DexCom (DXCM)
DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six months. At the same time, the S&P 500... 
Via StockStory
Topics Stocks
News headline image
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
News headline image
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
From DexCom, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.